[Comparative pharmacokinetic study of two different ways of using L-asparaginase as the main drug in combination chemotherapy].
OBJECTIVE
To search for a safer and more effective way of using L-asparaginase as the main drug in combination protocol.


METHODS
Twenty children with lymphoid malignancies were randomly divided into two groups: Group A and Group B, for L-asparaginase therapy. Group A: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times; Group B: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times. Blood samples were collected every day for group A and every other day for group B and serum L-asparaginase and L-asparagine levels were tested.


RESULTS
1. The pre-treatment mean value of serum L-asparaginase in group A was significantly higher than that in group B (P < 0.01). The levels of L-asparaginase in group A tended to increase day by day during the therapeutic course while those in group B without increasing tendency. 2. The L-asparagine levels and their dynamic changes were not significantly different between the two groups (P > 0.05).


CONCLUSIONS
The administration of Leunase by continuous intravenous injection every other day is a much safer and effective protocol and worthy of recommendation.
Wang
Y
Y
Shanghai Pediatric Medical Center, Shanghai Second Medical University, Shanghai 200092.
Jiang
H
H
Xie
X
X
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D001215:Asparaginase